A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)

被引：0
|
作者：
Y. Hodé
M. Reimold
A. Demazières
G. Reischl
F. Bayle
P. Nuss
A. Hameg
M. Dib
J. P. Macher
机构：
[1] FORENAP Research Institute For Neuroscience,Department of Nuclear Medicine
[2] Pharmacology and Psychiatry,Radiopharmacy
[3] Tübingen University Hospital,INSERM EMI
[4] University of Tübingen,E0117
[5] Université Paris V,undefined
[6] Hôpital Saint Antoine,undefined
[7] Aventis,undefined
来源：
Psychopharmacology | 2005年 / 180卷
关键词：
Positron emission tomography (PET); Cyamemazine; Dopamine D; Serotonin 5-HT; [; C]Raclopride; [; C]; -methyl-spiperone; Receptor occupancy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：377 / 384
页数：7
相关论文
共 50 条
  • [1] A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)
    Hodé, Y
    Reimold, M
    Demaziéres, A
    Reischl, G
    Bayle, F
    Nuss, P
    Hameg, A
    Dib, M
    Macher, J
    PSYCHOPHARMACOLOGY, 2005, 180 (02) : 377 - 384
  • [2] A positron emission tomography (pet) study of cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy of cyamemazine (Tercian®)
    Hode, Y
    Baylé, FJ
    Nuss, P
    Demazières, A
    Luthringer, R
    Reimold, M
    Hameg, A
    Dib, M
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S258 - S258
  • [3] Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy as measured by positron emission tomography (PET)
    Hode, Yann
    Benyamina, Amine
    Arbus, Christophe
    Reimold, Matthias
    PSYCHOPHARMACOLOGY, 2011, 217 (03) : 315 - 321
  • [4] Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy as measured by positron emission tomography (PET)
    Yann Hodé
    Amine Benyamina
    Christophe Arbus
    Matthias Reimold
    Psychopharmacology, 2011, 217 : 315 - 321
  • [5] Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects
    Arakawa, Ryosuke
    Ito, Hiroshi
    Takano, Akihiro
    Okumura, Masaki
    Takahashi, Hidehiko
    Takano, Harumasa
    Okubo, Yoshiro
    Suhara, Tetsuya
    PSYCHOPHARMACOLOGY, 2010, 209 (04) : 285 - 290
  • [6] Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects
    Ryosuke Arakawa
    Hiroshi Ito
    Akihiro Takano
    Masaki Okumura
    Hidehiko Takahashi
    Harumasa Takano
    Yoshiro Okubo
    Tetsuya Suhara
    Psychopharmacology, 2010, 209 : 285 - 290
  • [7] A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone
    Mamo, D
    Kapur, S
    Shammi, CM
    Papatheodorou, G
    Mann, S
    Therrien, FO
    Remington, G
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (05): : 818 - 825
  • [8] A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia
    Ragy R. Girgis
    Andy Forbes
    Anissa Abi-Dargham
    Mark Slifstein
    Neuropsychopharmacology, 2020, 45 : 786 - 792
  • [9] A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia
    Girgis, Ragy R.
    Forbes, Andy
    Abi-Dargham, Anissa
    Slifstein, Mark
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (05) : 786 - 792
  • [10] Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects
    Karlsson, P
    Dencker, E
    Nyberg, S
    Mannaert, E
    Boom, S
    Talluri, K
    Rossenu, S
    Eriksson, B
    Eerdekens, M
    Farde, L
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S386 - S386
12345